drugset / Trial / NCT01004510
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether the addition of the bisphosphonate Zometa (zoledronic acid) used along with standard regimens of chemotherapy, will help to control the need for palliative intervention of malignant pleural effusions due to non-small cell lung cancer.
Timeline
- Start
- 2009-11
- Primary completion
- 2010-09
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | 3 mg | Intravenous |
| Subject | Zoledronic acid | Other / unclassified | 3.3 mg | Intravenous |
| Subject | Zoledronic acid | Other / unclassified | 3.5 mg | Intravenous |
| Subject | Zoledronic acid | Other / unclassified | 4 mg | Intravenous |